Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07467213
PHASE4

Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction

Sponsor: Samsung Medical Center

View on ClinicalTrials.gov

Summary

This study aims to compare the clinical outcomes between routine use of potassium competitive acid blocker (P-CAB) and guideline-directed gastrointestinal (GI) protection strategy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) and being treated with dual antiplatelet therapy (DAPT).

Official title: Routine Use of Potassium Competitive Acid Blocker Versus Guideline-Directed Gastrointestinal Protection Strategy in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention on Dual Antiplatelet Therapy: A Randomized Trial

Key Details

Gender

All

Age Range

19 Years - Any

Study Type

INTERVENTIONAL

Enrollment

5000

Start Date

2026-04-01

Completion Date

2030-12-31

Last Updated

2026-03-12

Healthy Volunteers

No

Interventions

DRUG

Zastaprazan

Zastaprazan citrate 20mg will be administered orally once daily for gastrointestinal protection according to the study protocol.

DRUG

Proton Pump Inhibitors (PPI)

Guideline-directed gastrointestinal protection using various proton pump inhibitors as determined by the physician.